A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT04674813 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: CC-95266
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Bendamustine

Sponsor

Juno Therapeutics, a Subsidiary of Celgene